ECSP12011989A - Agonistas de mglu2 - Google Patents

Agonistas de mglu2

Info

Publication number
ECSP12011989A
ECSP12011989A ECSP12011989A ECSP12011989A EC SP12011989 A ECSP12011989 A EC SP12011989A EC SP12011989 A ECSP12011989 A EC SP12011989A EC SP12011989 A ECSP12011989 A EC SP12011989A
Authority
EC
Ecuador
Prior art keywords
mglu2 agonists
mglu2
agonists
schizophrenia
depression
Prior art date
Application number
Other languages
English (en)
Spanish (es)
Inventor
James Allen Monn
Lourdes Prieto
Martinez Lorena Taboada
Salgado Carlos Montero
Bruce William Shaw
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42026702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12011989(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP12011989A publication Critical patent/ECSP12011989A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ECSP12011989 2009-12-21 2012-06-20 Agonistas de mglu2 ECSP12011989A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09382290 2009-12-21
US30523910P 2010-02-17 2010-02-17

Publications (1)

Publication Number Publication Date
ECSP12011989A true ECSP12011989A (es) 2012-07-31

Family

ID=42026702

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12011989 ECSP12011989A (es) 2009-12-21 2012-06-20 Agonistas de mglu2

Country Status (35)

Country Link
US (1) US8318184B2 (cg-RX-API-DMAC7.html)
EP (1) EP2516406B1 (cg-RX-API-DMAC7.html)
JP (1) JP5779190B2 (cg-RX-API-DMAC7.html)
KR (1) KR101395356B1 (cg-RX-API-DMAC7.html)
CN (1) CN102695701B (cg-RX-API-DMAC7.html)
AR (1) AR079343A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010340039B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012017188B1 (cg-RX-API-DMAC7.html)
CA (1) CA2784667C (cg-RX-API-DMAC7.html)
CR (1) CR20120322A (cg-RX-API-DMAC7.html)
CY (1) CY1114880T1 (cg-RX-API-DMAC7.html)
DK (1) DK2516406T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2012000173A (cg-RX-API-DMAC7.html)
EA (1) EA020229B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP12011989A (cg-RX-API-DMAC7.html)
ES (1) ES2435651T3 (cg-RX-API-DMAC7.html)
HN (1) HN2012001160A (cg-RX-API-DMAC7.html)
HR (1) HRP20131052T1 (cg-RX-API-DMAC7.html)
IL (1) IL220011A (cg-RX-API-DMAC7.html)
JO (1) JO2978B1 (cg-RX-API-DMAC7.html)
MA (1) MA33824B1 (cg-RX-API-DMAC7.html)
MX (1) MX2012007332A (cg-RX-API-DMAC7.html)
MY (1) MY160618A (cg-RX-API-DMAC7.html)
NZ (1) NZ600305A (cg-RX-API-DMAC7.html)
PE (1) PE20121688A1 (cg-RX-API-DMAC7.html)
PH (1) PH12012501253A1 (cg-RX-API-DMAC7.html)
PL (1) PL2516406T3 (cg-RX-API-DMAC7.html)
PT (1) PT2516406E (cg-RX-API-DMAC7.html)
RS (1) RS53063B (cg-RX-API-DMAC7.html)
SG (1) SG181836A1 (cg-RX-API-DMAC7.html)
SI (1) SI2516406T1 (cg-RX-API-DMAC7.html)
TN (1) TN2012000281A1 (cg-RX-API-DMAC7.html)
TW (1) TWI477490B (cg-RX-API-DMAC7.html)
UA (1) UA107684C2 (cg-RX-API-DMAC7.html)
WO (1) WO2011084437A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2540728T1 (sl) 2010-02-17 2019-06-28 Takeda Pharmaceutical Company Limited Heterociklična spojina
AR083845A1 (es) * 2010-11-18 2013-03-27 Lilly Co Eli COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3
US9056844B2 (en) * 2010-11-18 2015-06-16 Eli Lilly And Company 4-substituted-3-benzyloxy-bicyclo[3.1.0]hexane compounds as mGluR 2/3 antagonists
ES2587204T3 (es) * 2011-06-17 2016-10-21 Eli Lilly And Company Derivados de ácido biciclo (3.1.0) hexano-2,6-dicarboxílico como agonistas del receptor mGlu2
AR089718A1 (es) * 2012-02-01 2014-09-10 Lilly Co Eli AGONISTAS DE mGlu2/3
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
HRP20191646T1 (hr) 2014-01-21 2019-12-13 Janssen Pharmaceutica Nv Kombinacije koje sadržavaju pozitivne alosteričke modulatore ili ortosteričke agoniste metabotropnog glutamatergičnog receptora podtip 2 i njihova uporaba
CN109999033B (zh) * 2014-01-21 2022-12-23 詹森药业有限公司 包括代谢型谷氨酸能受体亚型2的正别构调节物或正位激动剂的组合及其用途
UA123308C2 (uk) 2015-04-01 2021-03-17 Екебіа Терапьютікс, Інк. Композиції і способи для лікування анемії

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576323A (en) * 1993-12-03 1996-11-19 Eli Lilly And Company Excitatory amino acid receptor antagonists
GB9605429D0 (en) * 1995-11-16 1996-05-15 Lilly Co Eli Excitatory amino acid receptor antagonists
US5688826A (en) * 1995-11-16 1997-11-18 Eli Lilly And Company Excitatory amino acid derivatives
ZA983930B (en) 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
US7038077B2 (en) * 2001-01-11 2006-05-02 Eli Lilly And Company Prodrugs of excitatory amino acids
CN1267407C (zh) * 2001-01-11 2006-08-02 伊莱利利公司 兴奋性氨基酸前体药物
WO2002068380A1 (en) * 2001-02-22 2002-09-06 Eli Lilly And Company Synthetic excitatory amino acids
JP4342437B2 (ja) * 2002-06-11 2009-10-14 イーライ リリー アンド カンパニー 興奮性アミノ酸のプロドラッグ
US7381746B2 (en) * 2003-06-26 2008-06-03 Taisho Pharmaceutical Co., Ltd. 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative
AR083845A1 (es) * 2010-11-18 2013-03-27 Lilly Co Eli COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3
US9056844B2 (en) * 2010-11-18 2015-06-16 Eli Lilly And Company 4-substituted-3-benzyloxy-bicyclo[3.1.0]hexane compounds as mGluR 2/3 antagonists

Also Published As

Publication number Publication date
IL220011A (en) 2014-03-31
CA2784667A1 (en) 2011-07-14
CA2784667C (en) 2014-11-18
JP5779190B2 (ja) 2015-09-16
JP2013514974A (ja) 2013-05-02
CN102695701B (zh) 2014-10-01
HRP20131052T1 (hr) 2013-12-06
HN2012001160A (es) 2015-08-24
EA201290558A1 (ru) 2012-12-28
CN102695701A (zh) 2012-09-26
RS53063B (sr) 2014-04-30
BR112012017188A2 (pt) 2016-03-22
EA020229B1 (ru) 2014-09-30
NZ600305A (en) 2014-01-31
PL2516406T3 (pl) 2014-03-31
SG181836A1 (en) 2012-08-30
HK1171228A1 (en) 2013-03-22
TN2012000281A1 (en) 2013-12-12
MY160618A (en) 2017-03-15
TW201144290A (en) 2011-12-16
EP2516406B1 (en) 2013-09-18
PH12012501253A1 (en) 2014-08-01
CY1114880T1 (el) 2016-12-14
WO2011084437A1 (en) 2011-07-14
TWI477490B (zh) 2015-03-21
AU2010340039A1 (en) 2012-08-09
AR079343A1 (es) 2012-01-18
BR112012017188A8 (pt) 2016-10-04
IL220011A0 (en) 2012-07-31
PT2516406E (pt) 2013-10-10
CR20120322A (es) 2012-07-10
EP2516406A1 (en) 2012-10-31
PE20121688A1 (es) 2012-12-05
AU2010340039B2 (en) 2014-03-20
KR20120094056A (ko) 2012-08-23
US8318184B2 (en) 2012-11-27
DK2516406T3 (da) 2013-10-14
US20110152334A1 (en) 2011-06-23
MX2012007332A (es) 2012-07-20
UA107684C2 (xx) 2015-02-10
DOP2012000173A (es) 2012-11-30
KR101395356B1 (ko) 2014-05-14
BR112012017188B1 (pt) 2021-06-22
SI2516406T1 (sl) 2013-11-29
ES2435651T3 (es) 2013-12-20
MA33824B1 (fr) 2012-12-03
JO2978B1 (en) 2016-03-15

Similar Documents

Publication Publication Date Title
ECSP12011989A (es) Agonistas de mglu2
CY1125421T1 (el) Ριβονουκλεϊκα οξεα που περιεχουν ν1-μεθυλο- ψευδοουρακιλες και χρησεις αυτων
UY34484A (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
CO6612235A2 (es) Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus métodos de empleo
UY34342A (es) ?derivados de pirrolopirimidina y purina?.
MX2013002417A (es) Composiciones pesticidas.
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
DOP2011000386A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
GT201400033A (es) Pirimidinas anilladas sustituidas y uso de las mismas
CR11202S (es) Botella
MX373121B (es) Composiciones y metodos para el tratamiento de leucemia.
UY33504A (es) N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida deuterada, sales y usos de la misma
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
UY34472A (es) Derivados modificados de 4-fenil-piridina
CR20120362A (es) Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus métodos de empleo
CR20110202A (es) Antagonistas de la via hedgehog de ftalazina disustituida
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
BR112015009301A2 (pt) biocontrole de nematoides
CL2008001837A1 (es) Uso de compuestos derivados de cinolin-3-carboxamida en el tratamiento de la esquizofrenia.
CR20110361A (es) Derivados de 2-piridin-2-il-pirazol-3(2h)-ona, su preparación y su aplicación en terapeutica como activadores de hif
HN2009003469A (es) Biscocho lleno
CL2009000317A1 (es) Compuestos derivados de 3-alquil-piperazina sustituida; composicion farmaceutica; y su uso en el tratamiento de la depresion y ansiedad.
EA201391700A1 (ru) АГОНИСТЫ РЕЦЕПТОРА mGlu2
UY33207A (es) Métodos de preparación de tiazolidinas
CL2011002880S1 (es) Rodamiento de bola